Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02, Yahoo Finance reports. Armata Pharmaceuticals had a negative net margin of 887.54% and a negative return on equity of 139.56%.
Armata Pharmaceuticals Price Performance
Armata Pharmaceuticals stock opened at $2.68 on Wednesday. Armata Pharmaceuticals has a 52-week low of $0.83 and a 52-week high of $5.26.
Institutional Trading of Armata Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in shares of Armata Pharmaceuticals by 5.6% in the 4th quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock worth $91,000 after acquiring an additional 3,900 shares during the period. Vanguard Group Inc. raised its holdings in shares of Armata Pharmaceuticals by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company’s stock worth $1,335,000 after purchasing an additional 10,400 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Armata Pharmaceuticals in the 1st quarter worth approximately $95,000. Jane Street Group LLC bought a new stake in shares of Armata Pharmaceuticals in the 4th quarter worth approximately $25,000. Finally, HRT Financial LP bought a new stake in shares of Armata Pharmaceuticals in the 4th quarter worth approximately $52,000. 3.28% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
- Five stocks we like better than Armata Pharmaceuticals
- How to Invest in Grocery Stores
- Datadog is about to hit 52-week highs, and there’s more to come
- Consumer Staples Stocks, Explained
- Left for dead, Tower Semiconductor is a phoenix rising
- The How And Why of Investing in Oil Stocks
- 3 specialty apparel makers ready to spring higher
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.